Alaunos Therapeutics, Inc Financials

TCRT

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Alaunos Therapeutics, Inc (TCRT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 21 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 46/100

Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Alaunos Therapeutics, Inc has an operating margin of -48120.0%, meaning the company retains $-48120 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -685340.0% the prior year.

Growth

100

Alaunos Therapeutics, Inc's revenue surged 100.0% year-over-year to $10K, reflecting rapid business expansion. This strong growth earns a score of 100/100.

Leverage

100

Alaunos Therapeutics, Inc carries a low D/E ratio of 0.00, meaning only $0.00 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 3.98, Alaunos Therapeutics, Inc holds $3.98 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 78/100.

Cash Flow

While Alaunos Therapeutics, Inc generated -$5.0M in operating cash flow, capex of $0 consumed most of it, leaving -$5.0M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Alaunos Therapeutics, Inc generates a -226.8% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -557.2% the prior year.

Piotroski F-Score Weak

3/9

Alaunos Therapeutics, Inc passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Low Quality

1.06x

For every $1 of reported earnings, Alaunos Therapeutics, Inc generates $1.06 in operating cash flow (-$5.0M OCF vs -$4.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$10K

YoY+100.0%

Alaunos Therapeutics, Inc generated $10K in revenue in fiscal year 2024. This represents an increase of 100.0% from the prior year.

EBITDA

-$4.8M

YoY+84.9%

Alaunos Therapeutics, Inc's EBITDA was -$4.8M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 84.9% from the prior year.

Net Income

-$4.7M

YoY+86.7%

Alaunos Therapeutics, Inc reported -$4.7M in net income in fiscal year 2024. This represents an increase of 86.7% from the prior year.

EPS (Diluted)

$-2.92

YoY+86.7%

Alaunos Therapeutics, Inc earned $-2.92 per diluted share (EPS) in fiscal year 2024. This represents an increase of 86.7% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$5.0M

YoY+83.6%

Alaunos Therapeutics, Inc generated -$5.0M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 83.6% from the prior year.

Cash & Debt

$1.1M

YoY-82.0%

5Y CAGR-57.6%

10Y CAGR-30.7%

Alaunos Therapeutics, Inc held $1.1M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

YoY+0.0%

5Y CAGR-62.4%

10Y CAGR-34.8%

Alaunos Therapeutics, Inc had 2M shares outstanding in fiscal year 2024. This represents an increase of 0.0% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

-48120.0%

YoY+637220.0pp

Alaunos Therapeutics, Inc's operating margin was -48120.0% in fiscal year 2024, reflecting core business profitability. This is up 637220.0 percentage points from the prior year.

Net Margin

-46790.0%

YoY+656010.0pp

Alaunos Therapeutics, Inc's net profit margin was -46790.0% in fiscal year 2024, showing the share of revenue converted to profit. This is up 656010.0 percentage points from the prior year.

Return on Equity

-226.8%

YoY+330.4pp

5Y CAGR-102.8pp

10Y CAGR-132.9pp

Alaunos Therapeutics, Inc's ROE was -226.8% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is up 330.4 percentage points from the prior year.

Capital Allocation

R&D Spending

$362K

YoY-97.8%

5Y CAGR-60.6%

10Y CAGR-36.3%

Alaunos Therapeutics, Inc invested $362K in research and development in fiscal year 2024. This represents a decrease of 97.8% from the prior year.

Share Buybacks

N/A

Capital Expenditures

YoY-100.0%

Alaunos Therapeutics, Inc invested $0 in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 100.0% from the prior year.

TCRT Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	$10K+100.0%	$5K-99.8%	$2.9M+634.2%	$398K	$0	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$362K-97.8%	$16.3M-34.9%	$25.0M-49.6%	$49.6M-5.8%	$52.7M+37.5%	$38.3M
SG&A Expenses	$4.5M-63.5%	$12.2M-7.0%	$13.1M-52.3%	$27.6M-0.4%	$27.7M+41.7%	$19.5M
Operating Income	-$4.8M+86.0%	-$34.3M+2.4%	-$35.1M+54.7%	-$77.5M+3.5%	-$80.4M-38.9%	-$57.9M
Interest Expense	$0-100.0%	$1.9M-39.1%	$3.2M+165.3%	$1.2M	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$4.7M+86.7%	-$35.1M+6.9%	-$37.7M+52.1%	-$78.8M+1.5%	-$80.0M+32.1%	-$117.8M
EPS (Diluted)	$-2.92+86.7%	$-21.97-741.8%	$-2.61-605.4%	$-0.37+2.6%	$-0.38+45.7%	$-0.70

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Revenue	$0	$0-100.0%	$2K	N/A	$0-100.0%	$4K+300.0%	$1K	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$469K+153.5%	$185K-46.7%	$347K	N/A	$143K-20.6%	$180K+42.9%	$126K	N/A
SG&A Expenses	$718K-15.9%	$854K+14.3%	$747K	N/A	$1.0M+1.7%	$990K-38.8%	$1.6M	N/A
Operating Income	-$1.2M-14.2%	-$1.0M+4.9%	-$1.1M	N/A	-$1.1M+1.4%	-$1.2M+33.1%	-$1.7M	N/A
Interest Expense	N/A	N/A	N/A	N/A	$0	$0	$0	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$1.2M-10.3%	-$1.1M+2.1%	-$1.1M	N/A	-$1.1M+0.2%	-$1.1M+32.9%	-$1.7M	N/A
EPS (Diluted)	$-0.55+12.7%	$-0.63+6.0%	$-0.67	N/A	$-0.70+1.4%	$-0.71+32.4%	$-1.05	N/A

TCRT Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$2.8M-66.7%	$8.3M-87.3%	$64.9M-31.5%	$94.9M-35.2%	$146.3M+34.1%	$109.1M
Current Assets	$2.8M-66.7%	$8.3M-84.6%	$53.8M-31.8%	$78.8M-39.6%	$130.6M+23.8%	$105.5M
Cash & Equivalents	$1.1M-82.0%	$6.1M-84.5%	$39.1M-48.6%	$76.1M-33.9%	$115.1M+44.3%	$79.7M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$692K-64.6%	$2.0M-92.6%	$26.4M-28.3%	$36.8M+64.6%	$22.4M+58.6%	$14.1M
Current Liabilities	$692K-64.6%	$2.0M-91.9%	$24.2M+50.7%	$16.0M-12.7%	$18.4M+46.6%	$12.5M
Long-Term Debt	$0	$0	$0-100.0%	$16.3M	$0	N/A
Total Equity	$2.1M-67.3%	$6.3M-83.6%	$38.6M-33.6%	$58.1M-53.2%	$124.0M+30.5%	$95.0M
Retained Earnings	-$920.4M-0.5%	-$915.8M-4.0%	-$880.6M-4.5%	-$842.9M-10.3%	-$764.1M-11.7%	-$684.1M

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Total Assets	$3.7M-21.4%	$4.7M+123.3%	$2.1M-23.0%	$2.8M-22.4%	$3.5M-24.1%	$4.7M-22.5%	$6.0M-26.9%	$8.3M
Current Assets	$2.7M-28.2%	$3.7M+250.3%	$1.1M-61.3%	$2.8M-22.4%	$3.5M-24.1%	$4.7M-22.5%	$6.0M-26.9%	$8.3M
Cash & Equivalents	$1.9M-32.7%	$2.9M+802.5%	$319K-70.8%	$1.1M-35.2%	$1.7M-31.7%	$2.5M-40.6%	$4.1M-31.6%	$6.1M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$921K-14.2%	$1.1M+1.1%	$1.1M+53.5%	$692K-16.2%	$826K-8.9%	$907K-26.9%	$1.2M-36.6%	$2.0M
Current Liabilities	$921K-14.2%	$1.1M+1.1%	$1.1M+53.5%	$692K-16.2%	$826K-8.9%	$907K-26.9%	$1.2M-36.6%	$2.0M
Long-Term Debt	N/A	N/A	N/A	$0	N/A	N/A	$0	$0
Total Equity	$2.8M-23.4%	$3.7M+246.0%	$1.1M-48.7%	$2.1M-24.3%	$2.7M-27.8%	$3.8M-21.4%	$4.8M-23.9%	$6.3M
Retained Earnings	-$923.7M-0.1%	-$922.6M-0.1%	-$921.5M-0.1%	-$920.4M-0.1%	-$919.7M-0.1%	-$918.6M0.0%	-$918.9M-0.3%	-$915.8M

TCRT Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$5.0M+83.5%	-$30.1M-3.1%	-$29.2M+52.4%	-$61.5M-7.8%	-$57.0M-39.6%	-$40.9M
Capital Expenditures	$0-100.0%	$197K-8.8%	$216K-93.5%	$3.3M-66.0%	$9.8M+3343.0%	$284K
Free Cash Flow	-$5.0M+83.6%	-$30.3M-3.0%	-$29.4M+54.5%	-$64.8M+3.0%	-$66.8M-62.4%	-$41.1M
Investing Cash Flow	$0-100.0%	$1.3M+797.4%	-$193K+94.2%	-$3.3M+66.0%	-$9.8M-3343.0%	-$284K
Financing Cash Flow	$0+100.0%	-$18.1M-384.9%	$6.4M-75.3%	$25.8M-74.8%	$102.1M+72.6%	$59.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	$0-100.0%	$45K	$0	N/A	$653K

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Operating Cash Flow	-$844K-20.4%	-$701K+9.2%	-$772K-30.4%	-$592K+24.2%	-$781K+53.5%	-$1.7M+12.3%	-$1.9M+74.0%	-$7.4M
Capital Expenditures	N/A	N/A	N/A	$0	$0	$0	$0	$0
Free Cash Flow	N/A	N/A	N/A	-$592K+24.2%	-$781K+53.5%	-$1.7M+12.3%	-$1.9M+74.0%	-$7.4M
Investing Cash Flow	N/A	N/A	N/A	$0	$0	$0	$0-100.0%	$1.5M
Financing Cash Flow	$0	N/A	N/A	$0	$0	$0	$0	$0
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0

TCRT Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-48120.0%+637220.0pp	-685340.0%-684138.6pp	-1201.4%+18283.3pp	-19484.7%	N/A	N/A
Net Margin	-46790.0%+656010.0pp	-702800.0%-701508.8pp	-1291.2%+18495.4pp	-19786.7%	N/A	N/A
Return on Equity	-226.8%+330.4pp	-557.2%-459.3pp	-97.9%+37.8pp	-135.6%-71.1pp	-64.5%+59.5pp	-124.0%
Return on Assets	-169.8%+255.4pp	-425.3%-367.2pp	-58.1%+24.9pp	-83.0%-28.4pp	-54.6%+53.3pp	-108.0%
Current Ratio	3.98-0.2	4.22+2.0	2.23-2.7	4.91-2.2	7.11-1.3	8.42
Debt-to-Equity	0.000.0	0.000.0	0.00-0.3	0.28+0.3	0.00-0.1	0.15
FCF Margin	-49710.0%+557070.0pp	-606780.0%-605772.2pp	-1007.8%+15271.4pp	-16279.2%	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	-54600.0%	N/A	N/A	-29150.0%+145050.0pp	-174200.0%	N/A
Net Margin	N/A	N/A	-53650.0%	N/A	N/A	-28225.0%+139975.0pp	-168200.0%	N/A
Return on Equity	-41.3%-12.6pp	-28.7%+72.7pp	-101.4%	N/A	-41.4%-11.4pp	-29.9%+5.1pp	-35.1%	N/A
Return on Assets	-31.1%-8.9pp	-22.2%+28.4pp	-50.6%	N/A	-31.8%-7.6pp	-24.1%+3.7pp	-27.9%	N/A
Current Ratio	2.92-0.6	3.48+2.5	1.00-3.0	3.98-0.3	4.30-0.9	5.16+0.3	4.87+0.6	4.22
Debt-to-Equity	0.33+0.0	0.29-0.7	1.00+1.0	0.00-0.3	0.30+0.1	0.24+0.2	0.000.0	0.00
FCF Margin	N/A	N/A	N/A	N/A	N/A	-42025.0%+149675.0pp	-191700.0%	N/A

Similar Companies

Aptevo Therapeutics Inc APVO

$4.2M

Aditxt Inc ADTX

$500K

GRI Bio GRI

$3.5M

Xenetic Biosciences Inc XBIO

$6.9M

Clearmind Medici CMND

$1.4M

Frequently Asked Questions

What is Alaunos Therapeutics, Inc's annual revenue?

Alaunos Therapeutics, Inc (TCRT) reported $10K in total revenue for fiscal year 2024. This represents a 100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Alaunos Therapeutics, Inc's revenue growing?

Alaunos Therapeutics, Inc (TCRT) revenue grew by 100% year-over-year, from $5K to $10K in fiscal year 2024.

Is Alaunos Therapeutics, Inc profitable?

No, Alaunos Therapeutics, Inc (TCRT) reported a net income of -$4.7M in fiscal year 2024, with a net profit margin of -46790.0%.

What is Alaunos Therapeutics, Inc's earnings per share (EPS)?

Alaunos Therapeutics, Inc (TCRT) reported diluted earnings per share of $-2.92 for fiscal year 2024. This represents a 86.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Alaunos Therapeutics, Inc's EBITDA?

Alaunos Therapeutics, Inc (TCRT) had EBITDA of -$4.8M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Alaunos Therapeutics, Inc have?

As of fiscal year 2024, Alaunos Therapeutics, Inc (TCRT) had $1.1M in cash and equivalents against $0 in long-term debt.

What is Alaunos Therapeutics, Inc's operating margin?

Alaunos Therapeutics, Inc (TCRT) had an operating margin of -48120.0% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

What is Alaunos Therapeutics, Inc's net profit margin?

Alaunos Therapeutics, Inc (TCRT) had a net profit margin of -46790.0% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

What is Alaunos Therapeutics, Inc's return on equity (ROE)?

Alaunos Therapeutics, Inc (TCRT) has a return on equity of -226.8% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.

What is Alaunos Therapeutics, Inc's free cash flow?

Alaunos Therapeutics, Inc (TCRT) generated -$5.0M in free cash flow during fiscal year 2024. This represents a 83.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Alaunos Therapeutics, Inc's operating cash flow?

Alaunos Therapeutics, Inc (TCRT) generated -$5.0M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Alaunos Therapeutics, Inc's total assets?

Alaunos Therapeutics, Inc (TCRT) had $2.8M in total assets as of fiscal year 2024, including both current and long-term assets.

What are Alaunos Therapeutics, Inc's capital expenditures?

Alaunos Therapeutics, Inc (TCRT) invested $0 in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Alaunos Therapeutics, Inc spend on research and development?

Alaunos Therapeutics, Inc (TCRT) invested $362K in research and development during fiscal year 2024.

How many shares does Alaunos Therapeutics, Inc have outstanding?

Alaunos Therapeutics, Inc (TCRT) had 2M shares outstanding as of fiscal year 2024.

What is Alaunos Therapeutics, Inc's current ratio?

Alaunos Therapeutics, Inc (TCRT) had a current ratio of 3.98 as of fiscal year 2024, which is generally considered healthy.

What is Alaunos Therapeutics, Inc's debt-to-equity ratio?

Alaunos Therapeutics, Inc (TCRT) had a debt-to-equity ratio of 0.00 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Alaunos Therapeutics, Inc's return on assets (ROA)?

Alaunos Therapeutics, Inc (TCRT) had a return on assets of -169.8% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Alaunos Therapeutics, Inc's cash runway?

Based on fiscal year 2024 data, Alaunos Therapeutics, Inc (TCRT) had $1.1M in cash against an annual operating cash burn of $5.0M. This gives an estimated cash runway of approximately 3 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Alaunos Therapeutics, Inc's Piotroski F-Score?

Alaunos Therapeutics, Inc (TCRT) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Alaunos Therapeutics, Inc's earnings high quality?

Alaunos Therapeutics, Inc (TCRT) has an earnings quality ratio of 1.06x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Alaunos Therapeutics, Inc?

Alaunos Therapeutics, Inc (TCRT) scores 46 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.